Main content
Efficacy and safety of SARS-CoV-2 vaccines for individuals with haematological malignancies: protocol for a systematic review
Date created: | Last Updated:
: DOI | ARK
Creating DOI. Please wait...
Category: Project
Description: The objective of the systematic review is to assess the efficacy and safety of SARS-CoV-2 vaccines for individuals with haematological malignancies. We will limit inclusion to studies on the four vaccines currently authorized by the EMA and vaccines authorised in at least 10 countries worldwide (up to September 2, 2021), those are: • BNT162; • CX-024414 (mRNA-1273), and its equivalent TAK-919; • AZD1222 (ChAdOx1); • JNJ-78436735 (Ad26.COV2.S); • rAd26; • rAd5; • BBIBP-CorV (BIBP-CorV/ Covilo/ Hayat-Vax); • Sinovac (CoronaVac/ PiCoVac].
Start managing your projects on the OSF today.
Free and easy to use, the Open Science Framework supports the entire research lifecycle: planning, execution, reporting, archiving, and discovery.